
Roche subsidiary ImmunoGen has abandoned a Phase II trial into small-cell lung cancer (SCLC) after deciding that it was not …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

